文献速递神经免疫

奥瑞珠单抗对多发性硬化患者疫苗应答的影响:VELOCE研究

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
PubMed 文献 · Neurology · 2020-07-29

VELOCE研究将复发型多发性硬化患者按2:1随机分为奥瑞珠单抗组(n=68)和对照组(n=34),评估破伤风类毒素、23价肺炎球菌多糖疫苗、KLH及流感疫苗的应答。奥瑞珠单抗组对破伤风疫苗和肺炎球菌疫苗的阳性应答率及对KLH的体液应答均低于对照组,但流感疫苗仍可诱导一定程度的血清保护。

要点

  • 奥瑞珠单抗治疗降低对破伤风类毒素和23价肺炎球菌多糖疫苗的体液应答。
  • 奥瑞珠单抗治疗期间仍推荐接种季节性流感疫苗,可预期获得潜在保护性应答。
  • 标准非活疫苗在奥瑞珠单抗治疗期间仍应考虑接种。

核心结论

  • 奥瑞珠单抗治疗的多发性硬化患者对临床相关疫苗和新抗原KLH的体液应答减弱,但流感疫苗仍可诱导潜在保护性应答。

研究设计与样本

  • VELOCE为IIIb期随机对照研究(NCT02545868),复发型多发性硬化患者按2:1随机分为奥瑞珠单抗组(n=68,600 mg)和对照组(n=34,干扰素β或无疾病修饰治疗)。

主要发现

  • 8周时破伤风疫苗阳性应答率奥瑞珠单抗组为23.9%,对照组为54.5%。
  • 4周时对23价肺炎球菌多糖疫苗≥5个血清型阳性应答率奥瑞珠单抗组为71.6%,对照组为100%。
  • Prevnar未增强对与Pneumovax共同血清型的应答。
  • 奥瑞珠单抗组对KLH的体液应答低于对照组。
  • 4周时对5株流感病毒的血清保护率奥瑞珠单抗组为55.6%–80.0%,对照组为75.0%–97.0%。

临床怎么用

  • 奥瑞珠单抗治疗期间可接种标准非活疫苗,但需知晓体液应答可能减弱。
  • 推荐奥瑞珠单抗治疗患者接种季节性流感疫苗,可预期潜在保护性应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The phase IIIb A Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Participants With Relapsing Forms of Multiple Sclerosis (VELOCE) study (NCT02545868) assessed responses to selected vaccines in ocrelizumab (OCR)-treated patients with relapsing multiple sclerosis. METHODS: Patients were randomized 2:1 into the OCR group (n = 68; OCR 600 mg) or control group (n = 34; interferon beta or no disease-modifying therapy). All received tetanus toxoid (TT)-containing vaccine, Pneumovax (23-valent pneumococcal polysaccharide vaccine [23-PPV]), and keyhole limpet hemocyanin (KLH). The OCR group was subdivided into OCR1 (n = 33) and OCR2 (n = 35) at randomization. The OCR1 group received Prevnar (13-valent conjugate pneumococcal vaccine) 4 weeks after 23-PPV; the OCR2 and control groups received influenza vaccine. Vaccinations started 12 weeks after OCR initiation (OCR group) or on day 1 (control group). RESULTS: Positive response rate to TT vaccine at 8 weeks was 23.9% in the OCR vs 54.5% in the control group. Positive response rate to ≥5 serotypes in 23-PPV at 4 weeks was 71.6% in the OCR and 100% in the control group. Prevnar did not enhance response to pneumococcal serotypes in common with Pneumovax. Humoral response to KLH was decreased in the OCR vs control group. Seroprotection rates at 4 weeks against 5 influenza strains ranged from 55.6% to 80.0% in the OCR2 group and 75.0% to 97.0% in the control group. CONCLUSION: Peripherally B-cell-depleted OCR recipients mounted attenuated humoral responses to clinically relevant vaccines and the neoantigen KLH, suggesting that use of standard nonlive vaccines while on OCR treatment remains a consideration. For seasonal influenza vaccines, it is recommended to vaccinate patients on OCR because a potentially protective humoral response, even if attenuated, can be expected. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence confirming that the humoral response to nonlive vaccines in patients with relapsing multiple sclerosis after OCR treatment is attenuated compared with untreated or interferon beta-treated patients, but they can still be expected to be protective. CLINICALTRIALSGOV IDENTIFIER: NCT02545868.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020. PMID: 32727835. doi:10.1212/WNL.0000000000010380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。